Sarepta Therapeutics Inc (BSP:S1RP34)
R$ 37.72 -0.52 (-1.36%) Market Cap: 72.06 Bil Enterprise Value: 73.29 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 79/100

Sarepta Therapeutics Inc to Announce Results of Phase I/IIa Gene Transfer Clinical Trial using MYO-101 - Conference Call Transcript

Feb 27, 2019 / 01:00PM GMT
Operator

Good morning, ladies and gentlemen, and welcome to the Sarepta Therapeutics limb-girdle muscular dystrophy type 2E data conference call. As a reminder, today's program is being recorded. I'll now turn the call over to Doug Ingram, President and CEO of Sarepta Therapeutics. Please go ahead.

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Thank you very much. This is Doug Ingram. I'm the Chief Executive Officer for Sarepta. Thank you for joining our webcast this morning to report the results of our first cohort of patients in our limb-girdle 2E program. Please understand that we will be making forward-looking statements, and I would refer you to our public filings for obviously the various risks and uncertainties that come with making forecasts about the future.

We're excited to be reporting results today. This is an extremely important milestone for Sarepta. Our collaborator, Dr. Jerry Mendell wishes he could be with us today, and he sends his well wishes, but he is in Columbus, Ohio, and he's continuing to dose patients in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot